Date: 2015-05-21
Type of information: Collaboration agreement
Compound: VIS513
Company: Visterra (USA - MA) Agency for Science, Technology and Research (A*STAR) (Singapore)
Therapeutic area: Infectious diseases
Type agreement: collaboration development
Action mechanism: monoclonal antibody. VIS513 is a humanized monoclonal antibody that is designed to bind and potently neutralize all four serotypes of dengue virus. This antibody is targeting Dengue virus E protein Domain III. The company’s preclinical studies of VIS513 in animal models have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a single administration treatment for dengue virus infection.
Disease: dengue fever
Details: * On May 21, 2015, Visterra, a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research (A*STAR), Singapore, announced a collaboration to further the development of VIS513, Visterra’s broadly neutralizing antibody for the treatment of dengue fever. The collaboration combines Visterra’s expertise in therapeutic antibodies for challenging infectious diseases with D3’s proficiency in bringing early stage discoveries into clinical development. D3 and Visterra will also work together with infectious disease experts at Duke-National University of Singapore (Duke-NUS) to generate additional data necessary to initiate clinical trials of VIS513. Upon completion of these activities, D3 and Visterra will advance VIS513 through proof-of-concept clinical trials in humans, which will be conducted in Singapore. Under the terms of the collaboration agreement, Visterra retains all rights to develop and commercialize VIS513 globally.
Financial terms:
Latest news:
